Arcus Biosciences, Inc. (NYSE:RCUS) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Arcus Biosciences, Inc. (NYSE:RCUS) have been given a consensus rating of “Moderate Buy” by the twelve ratings firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and eight have given a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $30.20.

Several research analysts have recently issued reports on RCUS shares. Truist Financial set a $30.00 price target on shares of Arcus Biosciences in a report on Friday, December 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcus Biosciences in a report on Wednesday, January 21st. HC Wainwright restated a “buy” rating and set a $32.00 price objective on shares of Arcus Biosciences in a research report on Monday, March 2nd. Wells Fargo & Company set a $23.00 target price on Arcus Biosciences and gave the stock an “equal weight” rating in a report on Thursday, February 12th. Finally, Wall Street Zen upgraded Arcus Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th.

Insider Buying and Selling

In other Arcus Biosciences news, CFO Robert C. Goeltz II sold 6,552 shares of the business’s stock in a transaction that occurred on Wednesday, December 31st. The shares were sold at an average price of $23.38, for a total transaction of $153,185.76. Following the sale, the chief financial officer directly owned 67,924 shares of the company’s stock, valued at $1,588,063.12. The trade was a 8.80% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, President Juan C. Jaen sold 31,823 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $21.41, for a total transaction of $681,330.43. Following the completion of the transaction, the president owned 922,240 shares of the company’s stock, valued at approximately $19,745,158.40. This trade represents a 3.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 9.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Arcus Biosciences

A number of hedge funds have recently modified their holdings of the business. Hantz Financial Services Inc. increased its holdings in Arcus Biosciences by 121.9% in the fourth quarter. Hantz Financial Services Inc. now owns 1,604 shares of the company’s stock valued at $38,000 after purchasing an additional 881 shares during the period. T. Rowe Price Investment Management Inc. acquired a new position in Arcus Biosciences during the 4th quarter worth about $39,000. GAMMA Investing LLC lifted its holdings in Arcus Biosciences by 59.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock worth $37,000 after buying an additional 1,021 shares during the period. SBI Securities Co. Ltd. grew its position in shares of Arcus Biosciences by 13,547.6% in the 3rd quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company’s stock valued at $39,000 after buying an additional 2,845 shares during the last quarter. Finally, Abich Financial Wealth Management LLC bought a new stake in shares of Arcus Biosciences in the 3rd quarter valued at about $69,000. Institutional investors and hedge funds own 92.89% of the company’s stock.

Arcus Biosciences Trading Down 5.5%

RCUS opened at $20.23 on Wednesday. The company has a market cap of $2.54 billion, a P/E ratio of -6.13 and a beta of 0.85. The company has a current ratio of 4.36, a quick ratio of 4.36 and a debt-to-equity ratio of 0.16. The company’s 50 day moving average is $21.51 and its 200-day moving average is $19.98. Arcus Biosciences has a 1-year low of $6.50 and a 1-year high of $26.40.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings data on Wednesday, February 25th. The company reported ($0.89) EPS for the quarter, beating the consensus estimate of ($1.11) by $0.22. Arcus Biosciences had a negative net margin of 142.91% and a negative return on equity of 65.77%. The business had revenue of $33.00 million during the quarter, compared to the consensus estimate of $24.94 million. During the same quarter in the prior year, the firm earned ($1.03) EPS. The firm’s revenue was down 8.3% compared to the same quarter last year. Equities research analysts predict that Arcus Biosciences will post -3.15 earnings per share for the current fiscal year.

Arcus Biosciences Company Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.